Literature DB >> 18094374

p53--master and commander.

William D Foulkes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18094374     DOI： 10.1056/NEJMp0707422

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  19 in total

Review 1.  Biomarkers predicting malignant progression of laryngeal epithelial precursor lesions: a systematic review.

Authors:  Juan P Rodrigo; Juana María García-Pedrero; Carlos Suárez; Robert P Takes; Lester D R Thompson; Pieter J Slootweg; Julia A Woolgar; William H Westra; Ruud H Brakenhoff; Alessandra Rinaldo; Kenneth O Devaney; Michelle D Williams; Douglas R Gnepp; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-12       Impact factor: 2.503

2.  Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan.

Authors:  Yone-Han Mah; Ching-Sheng Hsu; Chen-Hua Liu; Chun-Jen Liu; Ming-Yang Lai; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2011-02-06       Impact factor: 6.047

Review 3.  Personalizing lung cancer prevention through a reverse migration strategy.

Authors:  Kathryn A Gold; Edward S Kim; Ignacio I Wistuba; Waun K Hong
Journal:  Top Curr Chem       Date:  2013

4.  MicroRNA-125b is a novel negative regulator of p53.

Authors:  Minh T N Le; Cathleen Teh; Ng Shyh-Chang; Huangming Xie; Beiyan Zhou; Vladimir Korzh; Harvey F Lodish; Bing Lim
Journal:  Genes Dev       Date:  2009-03-17       Impact factor: 11.361

5.  Two-round coamplification at lower denaturation temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinoma.

Authors:  Jin Li; Coren A Milbury; Cheng Li; G Mike Makrigiorgos
Journal:  Hum Mutat       Date:  2009-11       Impact factor: 4.878

6.  The carboxy-terminal domain of connexin 43 (CT-Cx43) modulates the expression of p53 by altering miR-125b expression in low-grade human breast cancers.

Authors:  Raihana Maqbool; Rabiya Rashid; Rehana Ismail; Saif Niaz; Nisar Ahmad Chowdri; Mahboob Ul Hussain
Journal:  Cell Oncol (Dordr)       Date:  2015-09-03       Impact factor: 6.730

7.  Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.

Authors:  Kathleen M Darcy; William E Brady; John W McBroom; Jeffrey G Bell; Robert C Young; William P McGuire; R Ilona Linnoila; Denver Hendricks; Tomas Bonome; John H Farley
Journal:  Gynecol Oncol       Date:  2008-10-02       Impact factor: 5.482

8.  Adenovirally mediated p53 overexpression diversely influence the cell cycle of HEp-2 and CAL 27 cell lines upon cisplatin and methotrexate treatment.

Authors:  Sandra Kraljević Pavelić; Marko Marjanović; Miroslav Poznić; Marijeta Kralj
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-23       Impact factor: 4.553

9.  HOPS/TMUB1 retains p53 in the cytoplasm and sustains p53-dependent mitochondrial apoptosis.

Authors:  Marilena Castelli; Danilo Piobbico; Martina Chiacchiaretta; Cinzia Brunacci; Stefania Pieroni; Daniela Bartoli; Marco Gargaro; Francesca Fallarino; Paolo Puccetti; Silvia Soddu; Maria Agnese Della-Fazia; Giuseppe Servillo
Journal:  EMBO Rep       Date:  2019-12-23       Impact factor: 8.807

10.  Hops/Tmub1 Heterozygous Mouse Shows Haploinsufficiency Effect in Influencing p53-Mediated Apoptosis.

Authors:  Simona Ferracchiato; Nicola Di-Iacovo; Damiano Scopetti; Danilo Piobbico; Marilena Castelli; Stefania Pieroni; Marco Gargaro; Giorgia Manni; Stefano Brancorsini; Maria Agnese Della-Fazia; Giuseppe Servillo
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.